PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB, DURVA) plus BEVACIZUMAB (BEV) IN BEV-NAIVE PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM)

被引：0
|
作者：
Reardon, David [1 ]
Kaley, Thomas [2 ]
Dietrich, Jorg [3 ]
Clarke, Jennifer [4 ]
Dunn, Gavin [5 ]
Lim, Michael [6 ]
Cloughesy, Tim [7 ]
Gan, Hui [8 ]
Park, Andrew [9 ]
Schwarzenberger, Paul [9 ]
Ricciardi, Toni [9 ]
Macri, Mary [9 ]
Ryan, Aileen [9 ]
Venhaus, Ralph [9 ]
机构：
[1] Dana Farber Canc Inst, Ctr Neurooncol, Boston, MA 02115 USA
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[3] Massachusetts Gen Hosp, Boston, MA 02114 USA
[4] Univ Calif San Francisco, San Francisco, CA 94143 USA
[5] Washington Univ, St Louis, MO USA
[6] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA
[7] Univ Calif Los Angeles, Neurooncol, Los Angeles, CA USA
[8] Austin Hosp, Melbourne, ACT, Australia
[9] Ludwig Inst Canc Res, New York, NY USA
来源：
NEURO-ONCOLOGY | 2018年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ATIM-38
引用
收藏
页码：10 / 10
页数：1
相关论文
共 50 条
  • [31] A phase 2, open-label, multicenter study of durvalumab (MEDI4736) tremelimumab in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS.
    O'Reilly, Eileen Mary
    Oh, Do-Youn
    Lee, Myung Ah
    Dhani, Neesha
    Armstrong, Jon
    Belli, Riccardo
    Ferro, Salvatore
    Ben, Yong
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [32] Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naive patients with advanced non small-cell lung cancer.
    Antonia, Scott Joseph
    Kim, Sang-We
    Spira, Alexander I.
    Ahn, Myung-Ju
    Ou, Sai-Hong Ignatius
    Stjepanovic, Neda
    Fasolo, Angela
    Jagert, Dirk
    Ottt, Patrick Alexander
    Wainberg, Zev A.
    Wakelee, Heather A.
    Goldman, Jonathan Wade
    Kurland, John
    Rebelatto, Marlon C.
    Yao, Wenliang
    Gupta, Ashok Kumar
    Blake-Haskins, John A.
    Segal, Neil Howard
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [33] A phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti-PD-L1 antibody, in combination with tremelimumab in patients with advanced solid tumors
    Callahan, Margaret K.
    Ott, Patrick Alexander
    Odunsi, Kunle
    Bertolini, Staphane V.
    Pan, Linda S.
    Venhaus, Ralph Rudolph
    Karakunnel, Joyson Joseph
    Hodi, F. Stephen
    Wolchok, Jedd D.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [34] EFFICACY AND SAFETY OF BEVACIZUMAB (BV) AND IRINOTECAN (I) IN ELDERLY PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORM (GBM): A MONOCENTRIC RETROSPECTIVE STUDY
    Robert, M.
    Leux, C.
    Gourmelon, C.
    Campone, M.
    Frenel, J.
    ANNALS OF ONCOLOGY, 2014, 25
  • [35] SAFETY AND EFFICACY OF BEVACIZUMAB AND METRONOMIC, ORAL ETOPOSIDE FOR RECURRENT GLIOBLASTOMA PATIENTS IN A PHASE II STUDY
    Reardon, David
    Desjardins, Annick
    Vredenburgh, James
    Rich, Jeremy
    Gururangan, Sridharan
    Sathornsumetee, Sith
    Friedman, Allan
    Friedman, Henry
    NEURO-ONCOLOGY, 2008, 10 (05) : 839 - 839
  • [36] Final analysis of the ELIXIR study: A prospective, multicenter, observational study to evaluate the efficacy and safety of atezolizumab plus bevacizumab (Atezo plus Bev) in Japanese patients with unresectable hepatocellular carcinoma (uHCC) in a real-world clinical setting
    Takehara, T.
    Kato, N.
    Aikata, H.
    Kuzuya, T.
    Hiasa, Y.
    Nakamura, S.
    Yamamoto, K.
    Morimoto, N.
    Sakamori, R.
    Kawamura, Y.
    Tsuchiya, K.
    Ueshima, K.
    Hiraoka, A.
    Nakano, M.
    Kokudo, N.
    Furuse, J.
    Moriguchi, M.
    Yamashita, T.
    Ikeda, M.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2024, 35 : S1480 - S1481
  • [37] A phase II trial with safety run-in of neoadjuvant therapy with an aromatase inhibitor in combination with durvalumab (MEDI4736) in postmenopausal patients with hormone-receptor-positive (HR plus ) breast cancer
    Khong, Hung T.
    Goodridge, Dawn N.
    Khakpour, Nazanin
    Lee, M. Catherine
    Laronga, Christine
    Armaghani, Avan J.
    Soyano-Muller, Aixa E.
    Han, Hyo
    Soliman, Hatem
    Costa, Ricardo
    Loftus, Loretta
    Hoover, Susan J.
    Kiluk, John V.
    Jameel, Zena
    Czerniecki, Brian J.
    CANCER RESEARCH, 2021, 81 (04)
  • [38] A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED PHASE 2 STUDY OF THE ERC-1671 (GLIOVAC) VACCINE IN COMBINATION WITH BEVACIZUMAB (BEV) IN RECURRENT GBM PATIENTS: SAFETY LEAD-IN ANALYSIS
    Bota, Daniela
    Carrillo, Jose
    Kong, Xiao-Tang
    Fu, Dan
    Chung, Jinah
    Pretto, Chrystel
    Strik, Ankie
    Schijns, Virgil
    Stathopoulos, Apostolos
    NEURO-ONCOLOGY, 2016, 18 : 22 - 22
  • [39] A RANDOMIZED PHASE 2 OPEN LABEL STUDY OF NIVOLUMAB PLUS STANDARD DOSE BEVACIZUMAB VERSUS NIVOLUMAB PLUS LOW DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA (GBM)
    Ahluwalia, Manmeet
    Fallah, Jaleh
    Peereboom, David
    Schilero, Cathy
    Ali, Assad
    Forst, Deborah
    Wong, Eric
    Wen, Patrick
    Reardon, David
    NEURO-ONCOLOGY, 2019, 21 : 220 - 220
  • [40] Efficacy and safety of bevacizumab (BEV) plus chemotherapy in Chinese patients (pts) with metastatic colorectal cancer (mCRC): Results from the ARTIST study.
    Guan, Z.
    Xu, J.
    Luo, R.
    Feng, F.
    Wang, L.
    Shen, L.
    Yu, S.
    Ba, Y.
    Liang, J.
    Wang, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345